US 7,476,662 B2
Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine
Frans Eduard Janssens, Bonheiden (Belgium); Joseph Elisabeth Leenaerts, Rijkevorsel (Belgium); Koenraad Arthur Van Rossem, Vosselaar (Belgium); Manuel Jesús Alcázar-Vaca, Toledo (Spain); Pedro Martínez-Jiménez, Madrid (Spain); José Manuel Bartolomé-Nebreda, Toledo (Spain); Antonio Gómez-Sánchez, Toledo (Spain); Francisco Javier Fernández-Gadea, Toledo (Spain); and Jos Van Reempts, Geel (Belgium)
Assigned to Janssen Pharmaceutica N.V., Beerce (Belgium)
Appl. No. 10/479,839
PCT Filed Jun. 11, 2002, PCT No. PCT/EP02/06576
§ 371(c)(1), (2), (4) Date Dec. 05, 2003,
PCT Pub. No. WO02/100862, PCT Pub. Date Dec. 19, 2002.
Claims priority of application No. 01202260 (EP), filed on Jun. 12, 2001.
Prior Publication US 2004/0167138 A1, Aug. 26, 2004
Int. Cl. A61K 31/00 (2006.01); A61P 43/00 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01); C07D 495/04 (2006.01); C07D 487/14 (2006.01)
U.S. Cl. 514—214.02  [540/578; 540/579] 19 Claims
 
1. A compound according to Formula (I),

OG Complex Work Unit Drawing
the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, wherein:
m is 1;
n is 1;
a, b, c independently are a single or a double bond;
X is a covalent bond or a bivalent C1-6alkanediyl radical wherein one or more —CH2— groups may be optionally replaced with —O—, —S—, —C(═O)— or NR7—; wherein:
R7 is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, Het, Het-alkyl, hydroxyalkyl, alkyloxy, alkyloxyalkyl, alkyloxyalkyloxyalkyl, aminoalkyl, mono- or dialkylaminoalkyl, formyl, alkylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, alkyloxycarbonyl, alkyloxycarbonylalkyl, alkylaminocarbonyl, alkylaminocarbonylalkyl, hydroxyalkyloxyalkyl, aminocarbonyl, aminocarbonylalkyl, alkyloxycarbonyl, alkylcarbonyl and alkylcarbonyloxyalkyloxyalkyl;
Y is —CH2—CH2—;
Z is N, in which case a is a double bond and b is a single bond; or is N—R7 in which case a is a single bond and R7 is defined as above;
R1, R2 independently are selected from the group consisting of hydrogen, hydroxy, alkyl, alkyloxy, Ar, Ar-alkyl, di(Ar—)alkyl, Het and Het-alkyl;
-A-B— independently is selected from the group consisting of a bivalent radical of formula
-E-CR8═CR8—  (a-1);
—CR8═CR8-E-  (a-2);
and
—CR8═CR8—CR8═CR8—  (a-3);
wherein:
R8 each independently is selected from the group consisting of hydrogen, halo, hydroxy, alkyl or alkyloxy;
E is selected from the group consisting of a bivalent radical of formula —O—, —S— and —NR7— wherein R7 is defined as above;
—C-D- independently is selected from the group consisting of a bivalent radical of formula
—CR8═CR8—CR8═CR8—  (b-1);
—N═CR8—CR8═CR8—  (b-2);
—CR8═N—CR8═CR8—  (b3);
—CR8═CR8—N═CR8—  (b-4);
and
—CR8═CR8—CR8═N—  (b-5);
wherein R8 is defined as above;
R3 is selected from the group consisting of hydrogen, halo, hydroxy, alkyl, oxo, alkyloxy, Ar, Ar-alkyl, di(Ar—)alkyl, Het and Het-alkyl;
R4 is selected from the group consisting of hydrogen, alkyl, amino, alkylamino, Ar-amino, Het-amino, Het-alkylamino, alkylcarbonylamino, Ar-carbonylamino, Het-carbonylamino, alkylaminocarbonylamino, Ar-aminocarbonylamino, Het-aminocarbonylamino, alkyloxyalkylamino, Ar-oxyalkylamino or Het-oxyalkylamino;
R5 is hydrogen and alkyl;
or R4 and R5 together may form a radical of Formula
-M-CR9═CR10—  (c-1);
—CR10═CR9-M-  (c-2);
-M-CR8R8—CR8R8—  (c-3);
—CR8R8—CR8R8-M-  (c-4);
—CR8═N—NR7—  (c-5);
—NR7—N═CR8—  (c-6);
—CR9═CR10—CR9═CR10—  (c-7);
—CR8R8—CR8R8—CR8R8-M-  (c-8);
-M—CR8R8—CR8R8—CR8R8—  (c-9);
—CR8R8—CR8═N—NR7—  (c-10);
—NR7—N═CR8—CR8R8—  (c-11);
═N—CR9═CR10—  (c-12);
or
—CR9═CR10—N═  (c-13);
wherein:
R7 and R8 are defined as above;
R9, R10 independently are selected from the group consisting of hydrogen, alkyl, halo and haloalkyl; or R9 and R10 together may form a bivalent radical of formula —CR8═CR8—CR8═CR8— wherein R8 is defined as above; and
M is selected from the group consisting of a bivalent radical of formula —CH2—, —O—, —S— and —NR7— wherein R7 is defined as above;
Ar is a homocycle selected from the group consisting of naphthyl and phenyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- or dialkylaminocarbonyl;
Het is a monocyclic heterocycle selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuryl, isoindolyl and benzothienyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with one or more halo, oxo, hydroxy, alkyl and alkyloxy radicals;
alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms; or is a a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein each carbon atom can be optionally substituted with one or more halo, hydroxy, alkyloxy or oxo radicals;
halo is a substituent selected from the group consisting of fluoro, chloro, bromo and iodo; and
haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbonatoms are substituted with one or more halo-atoms.